Be part of our #ACRO2022 Twitter conversation by following our Social Squad who will be leading the discussion online: Mona Arbab, MD MEd Tris Arscott, MD Parul Barry Avinash Chaurasia Idalid "Ivy" Franco MD MPH Michelle Gentile, MD PhD Arun Goel, MD William Ross Green, MD Jason Hirshberg Ryan Hughes Jenna Kahn, MD Sophia Kamran, MD Sarah Kilic, MD

One week until I'm back in Ft Lauderdale for #ACRO22 Who else is pumped to be back in person! Excited to be leading #DEI this year. ACRO - American College of Radiation Oncology ACROresident Brian Lally, MD William Ross Green, MD Neil K. Taunk Parul Barry Hina Saeed, MD Arun Goel, MD Idalid "Ivy" Franco MD MPH Ron DiGiaimo

Check out this post on theMednet, with comments led by Daniel E Spratt. Details impt takeaways, as well as limitations, of RTOG 0534 after prelim results presented in 2018. Check it out before Friday’s session at #acro2022. themednet.org/question/4357#…. 🏖🏖🏖

Excellent keynote speech by Wally Curran at #ACRO2022 Trainees: Wally stresses the importance of learning and understanding systemic treatments in addition to new radiation techniques ACRO - American College of Radiation Oncology ACROresident

Have I been pronouncing GETUG wrong the past few years? #ACRO2022, Stuti Ahlawat Neil K. Taunk Sonal Mayekar, MD Erin Gillespie, MD MPH Arun Goel, MD

So hot, not even off the press Alan Pollack showing RTOG 0543 SPPORT Do we have a winner (nodes *cough*) FFP was Phoenix definition Other clinical benefits to PLNRT too #ACRO2022 #prostatecancer

Sonal Mayekar, MD Neil K. Taunk Arun Goel, MD Brian Lally, MD Michelle Gentile, MD PhD This sounds like a music festival I would attend. Jimmy Buffett would be the logical headliner

Over the last 3 years, we have had several communications detailing the mission of the ABS and the #300in10 initiative. We are happy to announce that we have 4 training sites that are now taking applications. bit.ly/34Dn3My Daniel Petereit #ThisIsBrachytherapy #brachy

Thought provoking presentation by Dr. Steven Chmura at #ACRO22 on SBRT on oligomet. Tox from high-dose SBRT can happen late (BR001); no meaningful improvement in PFS in BR002 seen —>unlikely to proceed to phase III; and bell-shape curve of the utility of local therapy.

Now on Penn Clinical Podcasts, Neil K. Taunk reviews the benefits of #HDR-brachytherapy for #ProstateCancer. Listen in at spr.ly/6010KhAnG. American Brachy #PennDocTalks #radiotherapy

Thrilled to share #ASCENDE-SBRT is a go with CIHR funding- will greatly impact the way we care for people with unfavourable prostate cancer. Led by the unparalleled Dr. Andrew Loblaw with an incredible team Joelle Sebastien Hotte Gerard Morton Dr. Tamim Niazi CCTG

A recent study indicated a 1.2% ⬆️ risk of second primary cancers among men treated with radiation therapy vs. surgery for prostate cancer. Background smoking history remained unaccounted for, so we posted a comment asking the authors to clarify. #radonc jamanetwork.com/journals/jaman…

Alison Tree 💙 Simon Spohn This. Always wondered: MD1 gives flomax at low threshold - happier Pt but gr2 ctcae. MD2 gives less; Pt qol worse but gr1 ctcae. Which is the worse outcome? Composite endpoint of gr2 plus mcid needed? Phenomenal work once again!

Rectal Cancer Patients May Not Need Radiation, Study Finds - The New York Times ⁦The New York Times⁩ feel free to DM me. As Chair of large Radiation Onc Department I would be happy to inform you of danger of the article for pts. Easy fix. Worth it to fix. nytimes.com/2023/06/04/hea…

CTCAE GU tox G2+ was significantly worse in the two year analysis. Pts should know this. We chose to show tox plots over time as this shows it gets better, which is new information (no diff at 5 years). Cumulative graphs will be in the paper

Many agree critical questions remain re: clinical value of treating #ProstateCancer seen only on PET. So let’s get some answers & prove that our treatments help #patients more than they hurt ZERO Prostate Cancer UroToday.com

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI Chad Tang, MD & many others